JP2025521084A5 - - Google Patents
Info
- Publication number
- JP2025521084A5 JP2025521084A5 JP2024566249A JP2024566249A JP2025521084A5 JP 2025521084 A5 JP2025521084 A5 JP 2025521084A5 JP 2024566249 A JP2024566249 A JP 2024566249A JP 2024566249 A JP2024566249 A JP 2024566249A JP 2025521084 A5 JP2025521084 A5 JP 2025521084A5
- Authority
- JP
- Japan
- Prior art keywords
- recombinant polypeptide
- domain
- polypeptide according
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263340148P | 2022-05-10 | 2022-05-10 | |
| US63/340,148 | 2022-05-10 | ||
| PCT/US2023/021652 WO2023220118A2 (en) | 2022-05-10 | 2023-05-10 | Compositions and methods for controlled protein degradation in neurodegenerative disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025521084A JP2025521084A (ja) | 2025-07-08 |
| JP2025521084A5 true JP2025521084A5 (cg-RX-API-DMAC7.html) | 2026-05-19 |
Family
ID=88730934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024566249A Pending JP2025521084A (ja) | 2022-05-10 | 2023-05-10 | 神経変性疾患における制御されたタンパク質分解のための組成物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250326824A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4522739A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025521084A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023220118A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025238918A1 (ja) * | 2024-05-16 | 2025-11-20 | 国立研究開発法人理化学研究所 | モデルマウスおよびその作製方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595379B2 (en) * | 2003-05-30 | 2009-09-29 | Agensys, Inc. | Antibodies and related molecules that bind to PSCA proteins |
| CA2802349A1 (en) * | 2010-06-16 | 2011-12-22 | The Government Of The United States Of America As Represented By The Sec Retary Of The Department Of Health And Human Services | Anti-dr4 agonist antibodies |
| CN104854133B (zh) * | 2012-10-12 | 2018-10-30 | 新加坡科技研究局 | 用于制备重组抗体治疗剂的最佳重链和轻链信号肽 |
| EP3509622A4 (en) * | 2016-09-08 | 2020-06-17 | Regenerative Research Foundation | BIFUNCTIONAL ANTI-TAU POLYPEPTIDES AND USE THEREOF |
| US11629170B2 (en) * | 2016-10-12 | 2023-04-18 | Feldan Bio Inc. | Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell, uses thereof, methods and kits relating to same |
| US11273137B2 (en) * | 2018-09-04 | 2022-03-15 | Board Of Trustees Of Michigan State University | Methods and compositions to prevent and treat disorders associated with mutations in the ODC1 gene |
-
2023
- 2023-05-10 JP JP2024566249A patent/JP2025521084A/ja active Pending
- 2023-05-10 EP EP23804175.0A patent/EP4522739A4/en active Pending
- 2023-05-10 WO PCT/US2023/021652 patent/WO2023220118A2/en not_active Ceased
- 2023-05-10 US US18/864,325 patent/US20250326824A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ziemssen et al. | Glatiramer acetate: mechanisms of action in multiple sclerosis | |
| US20240000971A1 (en) | Compositions and methods for the treatment of tauopathy | |
| JP2024540221A (ja) | Aavカプシドバリアント及びその使用 | |
| KR20190134997A (ko) | 항-tau 항체 및 이의 사용 방법 | |
| AU2018248651B2 (en) | Genetic construct for use in the treatment of neurodegenerative disorder or stroke | |
| US9062125B2 (en) | Use of GIP for the treatment of disorders associated with dysfunctional synaptic transmission | |
| CN114364702B (zh) | 与间皮素特异性结合的抗-间皮素嵌合抗原受体 | |
| CN108350467A (zh) | 基因构建体 | |
| Perche et al. | Improved brain expression of anti-amyloid β scFv by complexation of mRNA including a secretion sequence with PEG-based block catiomer | |
| US20200277350A1 (en) | Proteinaceous heterodimer and use thereof | |
| CA2698780A1 (en) | Use of glp-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission | |
| CN113166777B (zh) | 含有AIMP2-DX2和miR-142的靶核酸的载体及其用途 | |
| JP2009519025A5 (cg-RX-API-DMAC7.html) | ||
| US20250064855A1 (en) | Use of dual-target CAR-T cells in treating B-cell autoimmune diseases | |
| JP2023544141A (ja) | AIMP2-DX2および必要に応じてmiR-142の標的配列ならびにその組成物を使用した神経系疾患を処置する方法 | |
| JP7428404B2 (ja) | Gsx1を使用した脊髄損傷(sci)および脳損傷の処置 | |
| JP2021534206A5 (cg-RX-API-DMAC7.html) | ||
| US20240009285A1 (en) | Compositions and Methods for Controlled Protein Degradation in Neurodegenerative Disease | |
| JP2023540130A5 (cg-RX-API-DMAC7.html) | ||
| JP2021514961A (ja) | 神経変性または神経炎症の治療または予防のための新規のil−4−/il−13−由来ペプチド化合物 | |
| US20250326824A1 (en) | Compositions and methods for controlled protein degradation in neurodegenerative disease | |
| Chiu et al. | Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein | |
| CN114805587B (zh) | Car-nk细胞及其在脏器和组织老化与纤维化治疗中的用途 | |
| WO2024245132A1 (en) | Optogenetic activation for signal transduction | |
| WO2025083294A2 (en) | Aat-fc fusion protein |